Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edwardo Ramos Cortes

Physical Medicine & Rehabilitation San Juan, PR Medical Doctor

NPI 1831152677 CMS profile 83078

Paseo Jose Celso Barbosa, Bo Monacillos, San Juan, PR 00935

Open in the dashboard

General payments

$247,008

346 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$148,558 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Edwardo Ramos Cortes of San Juan, PR is reported in the CMS Open Payments database as having received $247,008 across 346 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $148,558 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,020 47
2024 General $20,505 37
2023 General $39,112 71
2022 General $54,272 64
2021 General $51,602 49
2020 General $23,022 18
2019 General $33,476 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edwardo Ramos Cortes
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Edwardo Ramos Cortes were reported at $25,020. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Edwardo Ramos Cortes Physical Medicine & Rehabilitation median Middle half National median
2019 $33,476 $133 $45–$390 $163
2020 $23,022 $88 $29–$272 $114
2021 $51,602 $116 $33–$360 $132
2022 $54,272 $123 $40–$378 $149
2023 $39,112 $131 $43–$396 $160
2024 $20,505 $141 $45–$409 $164
2025 $25,020 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $116,666 126 payments
  2. Genentech USA, Inc. $53,249 55 payments
  3. Allergan Inc. $26,227 28 payments
  4. AbbVie, Inc. $22,871 16 payments
  5. PTC Therapeutics, Inc. $9,772 48 payments
  6. Sarepta Therapeutics, Inc. $9,718 11 payments
  7. Medtronic USA, Inc. $4,340 3 payments
  8. Genentech, Inc. $1,922 9 payments
  9. NS Pharma, Inc. $1,162 32 payments
  10. Catalyst Pharmaceuticals, Inc. $447 7 payments
  11. Other $635 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $184,980 78 payments
  2. Consulting Fee $37,252 19 payments
  3. Travel and Lodging $15,404 35 payments
  4. Food and Beverage $9,345 210 payments
  5. Education $28 4 payments
Products named General payments · program years 2019–2025
  1. SPINRAZA $116,390 123 payments
  2. Evrysdi $53,821 58 payments
  3. BOTOX Neuroscience $37,957 25 payments
  4. BOTOX Neuroscience $10,296 13 payments
  5. Elevidys $9,718 11 payments
  6. EMFLAZA $9,661 43 payments
  7. LIORESAL $3,560 2 payments
  8. VILTEPSO $1,162 32 payments
  9. SYNCHROMED $780 1 payment
  10. DYSPORT $163 2 payments
  11. Other $827 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

835

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$1,264,303

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

21.6%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Evrysdi Risdiplam Brand 45 $1,208,980
Botox Onabotulinumtoxina Brand 18 $25,770
Eliquis Apixaban Brand 30 $14,998
Tradjenta Linagliptin Brand 12 $6,315
Gabapentin Generic 125 $1,458
Baclofen Generic 64 $883
Lantus Insulin Glargine,hum.Rec.Anlog Brand 12 $786
Losartan Potassium Generic 62 $520
Pantoprazole Sodium Generic 19 $510
Atorvastatin Calcium Generic 55 $425

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$39,739

Medicare's payments for the services billed

Medicare patients

74

Average age 75

Services billed

587

42 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 50%
Heart failure 41%
Ischemic heart disease 41%
COPD 24%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPINRAZA
  • Biogen, Inc. $7,833
$7,833 — —
BOTOX
  • AbbVie, Inc. $7,119
$7,119 18 —
Evrysdi
  • Genentech USA, Inc. $4,196
  • Genentech, Inc. $141
$4,338 45 —
EMFLAZA
  • PTC Therapeutics, Inc. $138
$138 — —
VILTEPSO
  • NS Pharma, Inc. $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

346 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record